Cowen Reiterates Outperform Rating on Edwards Lifesciences (EW) following Pascal CLASP IID trial results
Tweet Send to a Friend
Cowen analyst Joshua Jennings reiterated an Outperform rating and $125.00 price target on Edwards Lifesciences (NYSE: EW) following Pascal CLASP ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
